Since the 1970s, pars plana vitrectomy (PPV) has been one of the most important ophthalmic surgeries for treating several blinding diseases by removing and replacing the diseased vitreous body.
1 2 3 Because the natural vitreous body is unable to regenerate, the vitreous cavity must be filled with suitable artificial materials, which can then keep the retina in place and prevent it from detaching again. Clinically, a number of artificial vitreous substitutes have been used, including silicone oil, heavy silicone oil, and polymeric gels.
4 5 6 7 8 9 10 11 However, these materials may lead to undesirable side effects and can induce severe complications, the most common of which is cataract formation in phakic eyes.
12 Therefore, it is necessary to perform PPV combined with lensectomy to remove the cataract and reserve the anterior lens capsule in some patients.
13 Recently, we devised a novel, foldable, artificial vitreous body consisting of a very thin (<30 μm thick) vitreous-like capsule with a silicone tube–valve system. This capsule can be folded and implanted into the vitreous cavity through a 1.5-mm incision in the sclera. Balanced salt solution (BSS; Alcon Ltd., Fort Worth, TX) was then injected into the capsule, which was filled to support the retina and to control intraocular pressure (IOP) through the tube–valve system, which is subsequently fixed under the conjunctiva.
14 Results from an animal study show that this novel artificial vitreous body device can effectively support the retina and control IOP and has good biocompatibility.
14 The main parameters of the encapsuled balanced salt solution vitreous body’s patellar fossa are as follows: central depth, 2.00 mm; radius of curvature, −6.00 mm; and capsule’s axial thickness, less than 30 μm. Because the axis is far thinner than the crystalline lens’ first and second surfaces (0.546 and 0.635 mm, respectively
15 ), the encapsuled balanced salt solution vitreous body’s index is thought to equal water’s (
n = 1.333).